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Abstract.  Cell surface heparan sulfate proteoglycan 
(HSPG) from metastatic mouse melanoma cells initi- 
ates cell adhesion to the synthetic peptide FN-C/H II, 
a heparin-binding peptide from the 33-kD A chain-de- 
rived fragment of fibronectin. Mouse melanoma cell 
adhesion to FN-C/H II was sensitive to soluble hepa- 
rin and pretreatment of mouse melanoma cells with 
heparitinase. In contrast, cell adhesion to the fibronec- 
tin synthetic peptide CS1  is mediated through an ot4B1 
integrin and was resistant to heparin or heparitinase 
treatment. 
Mouse melanoma cell HSPG was metabolically la- 
beled with [35S]sulfate and extracted with detergent. 
After HPLC-DEAE purification, 35S-HSPG eluted 
from a dissociative CL-4B column with a K,~ ,00.45, 
while 35S-heparan sulfate (HS) chains eluted with a 
K,v ,00.62.  The HSPG contained a major 63-kD core 
protein after heparitinase digestion. Polyclonal anti- 
bodies generated against HSPG purified from mouse 
melanoma cells grown in vivo also identified a 63-kD 
core protein. This HSPG is an integral plasma mem- 
brane component by virtue of its binding to Octyl 
Sepharose affinity columns and that anti-HSPG anti- 
body staining exhibited a cell surface localization. The 
HSPG is anchored to the cell surface through phos- 
phatidylinositol (PI) linkages, as evidenced in part by 
the ability of PI-specific phospholipase C to eliminate 
binding of the detergent-extracted HSPG to Octyl 
Sepharose. Furthermore, the mouse melanoma HSPG 
core protein could be metabolically labeled with 
3H-ethanolamine. 
The involvement of mouse melanoma cell surface 
HSPG in cell adhesion to fibronectin was also demon- 
strated by the ability of anti-HSPG antibodies and 
anti-HSPG IgG Fab monomers to inhibit mouse 
melanoma cell adhesion to FN-C/H II. 35S-HSPG and 
35S-HS bind to FN-C/H II affinity columns and require 
0.25 M  NaC1 for elution. However, heparitinase- 
treated 125I-labeled HSPG failed to bind FN-C/H II, 
suggesting that HS, and not HSPG core protein, binds 
FN-C/H II. These data support the hypothesis that a 
phosphatidylinositol-anchored HSPG on mouse mela- 
noma cells (MPIHP-63) initiates recognition to FN- 
C/H II, and implicate PI-associated signal transduction 
pathways in mediating melanoma cell adhesion to this 
defined ligand. 
T 
UMOR cell adhesion to components of  the extracellular 
matrix (ECM)  ~  and to other cells is critically impor- 
tant in the metastatic process (Liotta et al.,  1986; 
McCarthy et al.,  1985). Tumor cell adhesion-promoting 
fragments or synthetic peptides  of ECM proteins,  such as 
fibronectin (FN) and laminin, can inhibit the experimental 
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chondroitin sulfate;  OA, ovulbumin;  PG, proteoglyean;  PI, phosphatidyl- 
inositol; PLC, phospholipase C. 
metastasis of several metastatic tumor cell types (Barsky et 
al., 1984; McCarthy et al., 1985; Humphries et al., 1986; 
Saiki et ai., 1989). This inhibition is correlated with a corre- 
sponding  inhibition  of the arrest of ex vivo pretreated tu- 
mor cells within the pulmonary microcirculation after tail 
vein injection,  suggesting an importance of tumor cell sur- 
face receptors for these ligands in tumor cell arrest and/or 
extravasation.  One of these metastasis-inhibiting,  cell ad- 
hesion-promoting fragments is  a  33-kD  heparin-binding 
fragment that is derived from proteolytic digests of human 
plasma FN A-chains  (McCarthy et al.,  1988b).  Previous 
studies have demonstrated that the 33-kD heparin-binding 
fragment is active in promoting the RGD-independent  ad- 
hesion and spreading  of mouse melanoma, fibrosarcoma 
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(I-Iaugen et al., 1990), as well as other cell types (Herbst et 
al.,  1988; Liao et al., 1989; Wayner et al.,  1989; Visser et 
al.,  1989).  The heparin-binding  properties of the  33-kD 
fragment suggest the importance of cell surface proteogly- 
cans in mediating  cell adhesion  to this fragment. 
Cell surface proteoglycans  (PGs) have bean implicated  as 
receptors for the ECM, including  FN. Focal adhesion  for- 
marion by fibroblasts  on FN-coated substrata requires the 
coordinated recognition  of the heparin-binding  and RGD- 
containing  cell  binding  domains  (Laterra  et  al.,  1983; 
Woods et al., 1986; LeBaron et al., 1988). Analysis of focal 
adhesion  plaques reveal  areas enriched in PGs, integrins, 
and FN, as well as cytoskeletal proteins (Lattera et al., 1983; 
Lark and Culp,  1984; reviewed in Burridge et al.,  1988). 
Furthermore, cells deficient in heparan sulfate (HS) synthe- 
sis exhibit a different adhesion phenotype compared to cells 
that produce HS (LeBaron et al., 1988). Additionally, synde- 
can, a cell surface PG of mouse mammary epithelial  cells, 
has  been  shown  to  bind  the  carboxy-terminal,  heparin- 
binding  domain of FN and support attachment of epithelial 
cells (Saunders  et al.,  1988).  These data suggest that  cell 
surface PGs bind to the heparin-binding  domain of FN at 
sites  of contact between the cell and the substratum.  The 
structural  heterogeneity  of core proteins of cell surface PGs 
suggests several mechanisms by which cell surface PGs may 
modulate cell adhesion.  The core proteins of PGs may be 
linked to the cell membrane through  a transmembrane do- 
main (Saunders  et al.,  1988; Marynen et al.,  1989) or by 
covalent attachment to phosphatidylinositol  (PI) (Yanagishita 
and McQuillan,  1989; David et al.,  1990; Carey and Stahl, 
1990), suggesting that there may be specific functional con- 
sequences for these two types of plasma membrane linkages 
in mediating  cell recognition  of appropriate ligands. 
Several melanoma cell adhesion-promoting synthetic pep- 
tides have been identified from within the carboxy-terminal 
heparin  binding  domain of FN (McCarthy et al.,  1988a, 
1990;  Haugen  et  al.,  1990).  These  synthetic  peptides, 
termed FN-C/H I and FN-C/H II, are relatively hydrophilic, 
cationic,  and bind the glycosaminoglycan  (GAG) heparin, 
implicating  a  role for cell surface proteoglycans in medi- 
ating melanoma recognition of these synthetic peptides.  Ad- 
ditionally, a synthetic peptide located within the 33-kD frag- 
ment, termed CS1, promotes cell adhesion but does not bind 
heparin  (Humphries et al.,  1987; McCarthy et al.,  1990). 
Peptide CS1 interacts with ct4/31 integrin on human lympho- 
cytes and melanoma cells (Wayner et al., 1989; Mould et al., 
1990), indicating that ot4B1 integrin is also involved in medi- 
ating the adhesion of certain cells to this fragment.  The mul- 
tiple cell adhesion  promoting sites identified within the 33- 
kD fragment indicate  that melanoma cell adhesion to this 
fragment has a complex molecular basis, involving the possi- 
ble  close coordination  of cell  surface proteoglycans  and 
o~4B1 integrin. 
The current studies demonstrate that a cell surface hepa- 
ran  sulfate  proteoglycan (HSPG)  mediates  cell  adhesion 
of K1735 highly  metastatic mouse melanoma cells to pep- 
tide FN-C/H II (KNNQKSEPLIGRKKT), a heparin-bind- 
ing synthetic peptide from within the 33-kD heparin-binding 
fragment that is contiguous  with the ot4B1 integrin-binding 
sequence CS1 (DELPQLVTLPHPNLHGPEILDVPST). He- 
paritinase,  but not chondroitinase  ABC, treatment  of mela- 
noma cell surfaces completely inhibited cell adhesion to FN- 
C/H II. Purified cell surface lISP(} also bound to FN-C/H 
II affinity  columns and eluted at moderate ionic strength 
(0.25 M NaC1). Partial  characterization  of the HSPG core 
protein demonstrated that it has an apparent molecular mass 
of 63 kD, and that it is expressed by melanoma ceils as an 
integral plasma membrane protein that is attached by linkage 
to PI.  Polyclonal  antibodies  generated against  the mouse 
melanoma HSPG protein core stained the surface of mouse 
melanoma cells and inhibited  mouse melanoma cell adhe- 
sion to FN-C/H II. In addition  to demonstrating  a role for 
cell surface HSPG in the initial recognition  of FN-C/H-II, 
these studies suggest a role for PI-associated signal transduc- 
tion pathways in mediating  melanoma cell adhesion  to this 
defined heparin  binding  ligand. 
Materials and Methods 
Cell Culture 
A highly metastatic clone (M4) of the K1735 mouse melanoma was gener- 
ously provided by Dr. I. J. Fidler (M.D. Anderson Hospital Cancer Center, 
Houston, TX). This tumor cell line was maintained by in vitro culture in 
DMEM (Sigma Chemical Co., St. Louis, MO) supplemented with 10% calf 
serum (Signm Chemical Co.). The number of in vitro passages was limited 
to eight in order to minimize phenotypic drift. 
Peptide Preparation 
Peptides were synthesized at the University of Minnesota Microchemical 
Facility using a Beckman System 990 peptide synthesizer. The procedures 
used were based on the Merrifield solid phase system as described previ- 
ously (Stewart and Young, 1984). Lyophilized crude peptides were purified 
by preparative reverse-phase HPLC on a C-18 column, using an elution gra- 
dient of 0-60% acetonitrile with 0.1% trifluoroacetic acid in water. The pu- 
rity and composition of the peptides were verified by HPLC  analysis of 
hydrolysates prepared by treating the peptides under nitrogen in 6 N  HCI 
overnight at 100oc (Skubitz et al.,  1988; McCarthy et al.,  1990; Haugen 
et al.,  1990). All peptides were synthesized with a tyrosine residue at the 
carboxy-terminal end to facilitate radioiodination of the peptides. The se- 
quence  (minus  the  tyrosine  residue  at  the  carboxy  terminal  end)  and 
selected properties of the synthetic peptides used in this study are shown 
in Fig.  I. 
Conjugation of  Peptides to Ovaibumin 
Synthetic peptides were chemically conjugated to ovalbumin (OA) using 
1-ethyl-3(3-dimethyl-aminopropyl)-carbodiimide  hydrochloride  (EDC) 
(Sigma Chemical Co.) (Humphries et al.,  1987;  McCarthy et al.,  1990; 
Haugen et al., 1990). Briefly, equal amounts (by weight) of the peptides and 
OA were solubilized in water and mixed with a 10-fold excess (by weight) 
of EDC dissolved in water. The sample was mixed overnight at 40C on a 
circulator rotator.  The coupled  peptides were then dialyzed extensively 
against PBS or water to remove the excess EDC and uncoupled peptides 
(Spectrapore 6,  10 kD exclusion; Spectrum Medical Industries, Los An- 
geles, CA). The efficiency of peptide coupling to OA was evaluated using 
a  trace amount  of radioactive peptides  and was  determined  to  have a 
stoichiometry of 2.9 tool of FN-CIH II to 1 mol of OA and 6.3 tool of CS1 
to 1 tool of OA (Haugen et al.  1990). Peptide-OA conjugates were stored 
at -20~  until use. 
Cell Adhesion Assays 
Cell adhesion assays were performed as described previously with minor 
modifications (Haugen et aL, 1990). Briefly, peptide conjugates were diluted 
to various concentrations in Voller's carbonate buffer and 100-/zl aliquots 
were dispensed in triplicate into Immulon 1 polystyrene microtiter wells. 
The wells were incubated in a humidified oven at 37~  overnight. Radiola- 
beled OA-conjugates were used to quantitate the coating of OA-peptides to 
the wells and shown to be about the same for FN-C/H II-OA and CSI-OA 
(Hangen et al.,  1990).  Nonspecific sites were blocked the next day with 
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buffer for 2 h. Subcordtuent M4 K1735 mouse melanoma cells that had been 
radiolabeled  overnight  with  3H-thymidine (3HTdR, specific activity  6.7 
Ci/mmoi; NEN Research Products, Boston, MA) were harvested by release 
with trypsin/EDTA,  washed, and resuspended to a final concentration of 
5  x  104 cells per ml in DMEM supplemented with 20 mM Hepes and 
1 mg/ml BSA. 100-td aliquots of the cell suspension were dispensed into 
wells and the cells were incubated at 370C for various lengths of time. The 
assays were terminated by aspirating nonadherent cells, washing the wells 
three times, and solubilizing the bound cells in 0.5 N NaOH containing 1% 
SDS. Radioactivity was determined in a Beckman model 3801 liquid scintil- 
lation counter and used to calculate the pereentnge of cells that remained 
adherent  to  each  substratum.  We  have determined  through  35S-sulfate 
labeling experiments of mouse melanoma cells that HSPG is replenished 
to the cell surface within  15-30 min after trypsinization (not shown). 
To evaluate the inhibition of  cell adhesion with polyclonal anti-HSPG an- 
tibodies,  cells were preincubated with the antibody for  15-30 rain,  then 
plated directly into the wells precoated with substrata that promoted half- 
maximal cell adhesion, and allowed to attach for 15-30 min in the continued 
presence of antibody. For chondroitinase ABC treatment,  trypsin/EDTA- 
released cells were washed in PBS, 0.1% BSA, and 1.25 mM CaCI2 and in- 
cubated with or without 0.1  U/ml chondroitinase ABC (Sigma Chemical 
Co.) for 15 min at 37"C (Saunders and Bernfield,  1988). Cells were then 
diluted in DMEM, 20 mM Hepes, 0.1% BSA to 5  x  104 cell per ml with 
a concentration of 0.02 U/ml of enzyme and plated to coated substrata and 
incubated for 15-30 min. Alternatively, ceils were treated with increasing 
concentrations of  heparitinase enzyme  then plated in the continued presence 
of enzyme. Assays were harvested and adherent cells were quantitated as 
previously described. 
Proteoglycan PUrification 
Subconfluent cultures of K1735 M4 mouse melanoma cells were preferen- 
tially labeled with 35S-sulfate for 18 h by replacing the medium with RPMI 
1640 containing  0.1  mM Na2SO4, 0.36 mM glutamine,  and 50/~Ci/ml 
Na235SO4 (carrier  free, specific activity `*3 Ci/rng; ICN Biomedicals, Ir- 
vine, CA). In other experiments, the cells were doubly labeled for 18 h with 
35S-sulfate and 3H-ethanolamine (16 ~tCi/ml; Amersham International). An 
extraction  protocol  utilizing  detergent-mediated  cell  lysis  was  followed 
to  specifically  enrich  for  intact  plasma  membrane-associated  PGs 
(Yanagishita  and  Hascall,  1984). The  35S-labeled cell  cultures  were 
replaced with DMEM containing 50/~g/ml beparin for a 30-min incubation 
at 180C. The heparin extract was removed and detergent extraction buffer 
(10 mM Tris-HCl, 0.15 M NaCI, 5 mM MgCI2, 2 mM EDTA, 0.24 mM 
DTT,  1 mM PMSF, 1% Triton X-100, pH 7.2) was added and incubated at 
37"C for 15 rain. The detergent extracts were centrifuged at 1,500 rpm for 
5 rain to remove insoluble material, then dialyzed in small pore dialysis tub- 
ing (molecular weight cut off 3,500) against acetate buffer (0.5 M sodium 
acetate,  0.1  M  sodium sulfate,  10 mM EDTA, 0.1  mM PMSF,  10 mM 
6-aminohexanoic acid, 1% Triton X-100, pH 6.8) to remove unincorporated 
35S-sulfate (Oegema et al.,  1979). 
35S-PGs were purified by HPLC (Beckman Model  ll0A) using a 7.5 
x  75  mm TSK DEAE 5PW  anion exchange column  (Bio-Rad Labora- 
tories,  Richmond,  CA).  Extracts  were  dialyzed  against  HPLC-DEAE 
buffer (0.15 M Tris-HCl, 6.0 M Urea, 0.1 M NaC1, 0.01 M EDTA, 0.01 M 
6-aminohexanoic  acid,  0.2%  Triton  X-100, or 0.2%  CHAPS,  0.1  mM 
PMSF, pH 7.0) and applied at a flow rate of 1 ml/min, and proteins were 
eluted with a linear gradient from 0.1 M to 0.8 M NaCI (Klein et al., 1989). 
l-ml fractions were collected and sampled for the presence of 35S-sulfate 
by liquid scintillation (Beckman LS 3801). The salt gradient was monitored 
by  conductivity  measurements  using  a  Radiometer  Conductivity  Meter 
(model CDM 83). Comparisons were made to standards of known NaC1 
concentration in DEAE buffer to calculate the actual salt concentrations of 
the fractions. To insure adequate separation of 3SS-proteoglycans, HPLC- 
DEAE chromatographic peaks were pooled and each rechromatographed 
on the same column before further characterization.  The percent recovery 
from the HPLC-DEAE columns was 90-95 %. Samples were dialyzed into 
water containing 0.1 raM PMSF and lyophilized. Aliquots were stored at 
-80"C and used as indicated. 
HSPGs were characterized by gel filtration on Sepharose CL-4B (Sigma 
Chemical Co.) columns (0.9 ￿  110 cm) equilibrated in 10 mM Tris-HCl, 
pH 7.2, 4 M guanidine,  1% Triton X-100 at a flow rate of 3 ml/h (Klein 
et al., 1986). 1-ml fractions were collected with a 85-95%  recovery of ra- 
dioactivity. Rat chondrosarcoma CSPG (Oegema et al,,  1975) associated 
with  4%  hyaluronic acid  and  glucuronolactone  were  used  to mark  the 
column  void  (l/o) and  total  (Vt) volumes,  respectively. 35S-GAGs were 
released from protenglycan protein cores by alkaline/~-elimination in 0,05 N 
NaOH containing 1 M NaBI-14 over 24 h at 45~  (Oegema et al.,  1979). 
The reaction mixture was neutralized by the dropwise addition of  acetic acid 
and desalted  on  Sephadex G-50  (Sigma Chemical)  columns.  35S-GAGs 
were recovered from the column Vo with <5 % of alkali-treated material in- 
eluded in the column. The HS and CS content of 35S-GAG samples were 
determined  by  sequential  nitrous  acid  deaminative  cleavage and  chon- 
droitinase ABC treatment by methods modified from Conrad et al. (1977). 
Detergent-extracted 35S-macromoleculas  resistant to the effects of nitrous 
acid and chondroitinase ABC digestion were considered 35S-glycoproteins 
(Brown et al., 1981) and this population never exceeded 10% of the deter- 
gent extract. 
Detergent-extracted 35S-HSPGs, purified by ion exchange chromatogra- 
phy, were resuspended in Octyl Sepharose buffer (20 mM Tris-HC1, 4 M 
guanidine HC1, pH 6.8). Samples were applied to a 5 ml Octyl Sepharose 
CL4B (Sigma Chemical Co.) column at a flow rate of 0.5 ml/min. Hydro- 
phobic HSPGs were then eluted with a linear gradient of 0--0.5% Triton 
X-100 in Octyl Sepharose buffer (Yanagishita et al., 1987). 2-ml fractions 
were analyzed for 35S-radiolabel by liquid scintillation and percent Triton 
X-100 was determined by absorbance at 280 nm. 
Radioiodination of Heparan Sulfate Proteoglycan 
Sepharose  CL-4B-purified  HSPGs  aliquots  were  radioiodinated  using 
Na125I and iodobead  (Pierce Chemical  Co., Rockford,  IL)  in a 50-raM 
Tris-HCl, pH 7.0, 0.2 % CHAPS buffer. After a 15-rain incubation, the reac- 
tion mixture was applied to a 0.5-ml DEAE-Spetra/Gel column (Spectrum, 
Los Angeles, CA) equilibrated in DEAE buffer. Free Nat25I was removed 
by washing the column with 0.1 M NaC1 DEAE buffer. The 125I-HSPC~ 
were eluted from the column in DEAE buffer containing 1.0 M NaCI. The 
x25I-labeled HSPGs  were  dialyzed  into  deionized  water  with  0.1  mM 
PMSF and frozen at  -80~  Radioactivity was quantitated in a gamma 
counter (TM Analytic, Gamma Trac 1193). 
Enzyme Treatment 
Aliquots  of purified  HSPGs  were  digested  with  heparitinase  or chon- 
droitinase ABC (Sigma Chemical Co. and Seikngalm America Inc., Rock- 
ville, MD) in 50 mM Tris, pH 7.0, l0 mM calcium acetate,  1 mM PMSF, 
0.036 mM pcpstatin, and l0 mM NEM for 4 h at 37~  For the treatment 
with  PI-specific  phospholipase  C  (PI-PLC)  (Boehringer  Mannheim), 
HSPGs were solubilized in 50 mM Tris-HCl, 0.1% Triton X-100, l0 mM 
EDTA, pH 7.5, and incubated with 50 mU enzyme for 1-2 h at 370C (David 
et al,  1990). After the digestion, the treated and control HSPGs were ab- 
sorbed on DEAE, rinsed to remove Triton X-100, and eluted in 1.0 M NaC1 
DEAE  buffer  containing  CHAPS.  The  absence  of proteases  in  the 
heparitinase and PI-PLC enzymes were verified by a lack of digestion of 
azocasein after a 60-min incubation with the enzyme at 37~  (Tomarelli et 
al.,  1949). 
Peptide Affinity Chromatography 
OA-peptide conjugates were coupled to Affigel-10  beads (Bio-Rad Labora- 
tories) following packaging direction (1 mg OA/rnl gel).  1-10-ml bed vol- 
ume columns were made and equilibrated in 50 mM Tris-HC1, pH 7.0, 0.2% 
CHAPS,  50 mM NaCI,  1 mM PMSF, 0.01 M EDTA, 0.01 M 6-amino- 
hexanoic acid  (column buffer).  Bound material  was eluted with a linear 
NaCI salt gradient (0.05-0.5 M) in column buffer. 
Antibody Preparation 
K1735 M4 tumor cells were injected into the leg flanks of C57B169  x 
C3HHeNo" F1 mice. Tumors were metabolically radiolabeled in vivo by 
intraperitoneal injection of 35S-sulfate 24 h before tumor excision and ex- 
tracted overnight in guanidine extraction buffer (4 M guanidine, 2 % Triton 
X-100, 0.1M NaC1, 0.5 mM PMSF, 0.1 M 6-aminohexannic acid,  10 mM 
EDTA, 1 mg/ml benzamidine) at 4oC. The extract was centrifuged at 5,500 
rpm for 30 min at 4~  and the supernatant was dialyzed into 0.1 M NaCI 
DEAE buffer containing 0.2%  Triton X-100. DEAE-Sephacel was added 
to form a slurry and incubated overnight at 4~  with rotation. The DEAE- 
Sephacel slurry was washed with DEAE buffer containing 0.2% CHAPS, 
then ba~h eluted in 1.0 M NaC! DEAl/buffer. 35S-macromolecules  in the 
eluate were precipitated with 4 vol of ethanol at 40C overnight, and col- 
lected after centrifugetion at 5,500 rpm for 30 min.  The precipitate was 
resuspended in guanidine extraction buffer and separated by CsCI density 
gradient ultracentrifugation (0.,*4 g of CsCl/g of  extract) at 40,000 rpm and 
40C for 60 h using a Ti-70 rotor and a Beckman model L5-65 ultracen- 
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a top 3/5 (low buoyant density) fraction (Oegema et al., 1979). The high 
buoyant density fraction (p ffi 1.44) was dialyzed into DEAE buffer with 
0.2 % Triton X-100 and purified by HPLC-DEAE ion exchange column 
chromatography  (see above). HSPGs eluted as a single peak (0.32 M NaC1) 
from HPLC-DEAE columns and were dialyzed against water with 0.5 mM 
PMSF and lyophilized. Lyophilized  tumor-extracted PGs were determined 
to be HSPG by GAG analysis (see proteoglycan  purification). Samples  were 
electrophoresed in a preparative 0.6% agarose-l.8% polyacrylamide gel 
(Klein et al., 1986), and visualized by staining with 0.2% toluidine blue 
in 0.1 N acetic acid. A rat chondrosarcoma CSPG (Mr 2.6  x  106) and 
chondroitin 4-sulfnte (Mr 20,000) were used as markers. HSPG bands were 
excised and used to immunize New Zealand White rabbits. Immunization 
was performed by homogenizing equal volume of excised HSPG gel with 
complete Freund's adjuvant and injecting mixture into hind legs of rabbits. 
Subsequent biweeldy boost of HSPG and incomplete Freund's adjuvant 
mixture were injected. Sera were collected 7-10 d after the sixth immuniza- 
tion, and tested by Western blot after transfer of HSPG from agarose- 
polyacrylamide  gel to a nylon membrane. IgG was purified from pooled im- 
mune sera as previously described (Skubitz et al., 1988; McCarthy et al., 
1990), and adsorbed on FN, type IV collagen or laminin affinity  columns to 
remove any potential cross reacting antibodies to these ECM components. 
Fab monomers were generated by digestion of  polyclonai  anti-HSPG  IgG 
and normal rabbit IgG with papain-agarose  (Sigma Chemical Co.) in buffer 
containing 100 mM sodium acetate, 50 mM cysteine, I mM EDTA, pH 5.5, 
for 6 h at 37~  with gentle agitation. The papain-agarose was removed  by 
centrifugation, and undigested  IgG and Fc fragments were removed  by pro- 
tein A-agarose (Pierce Chemical Co.) affinity column chromatography. 
Digestion and purification was monitored by SDS-PAGE. 
lmmunofluorescence 
K1735 M4 mouse melanoma cells grown in tissue culture were released by 
treatment with trypsin/ElYrA  and allowed  to adhere on glass coverslips  over- 
night. Cells were then fixed with 4% paraformaldehyde  in PBS for 20 rnin 
at room temperature. Coverslips were blocked in PBS containing 5 mg/mi 
BSA and 5 % normal goat sera for 1-2 h. Anti-HSPG  antibodies diluted 1:50 
in PBS were added to the coverslips  and incubated for 1 h at room tempera- 
ture,  coverslips were washed then incubated for  1 h with rhodamine- 
conjugated goat anti-rabbit IgG (1:250) (Cooper Biomedical, Malvern, 
PA). The coverslips were washed and mounted with a polyvinyl  alcohol so- 
lution to slides. Cells were photographed for 30 s on Tfi-X Pan 35-ram film 
with a Zeiss Model IM microscope using a 63￿  planapochromat lens. 
Results 
Peptide FN-C/H H Initiates Mouse Melanoma 
Adhesion by an HS-dependent Mechanism 
The location, primary sequences, and selected characteris- 
tics of FN-C/H II and CS1 within the 33-kD fragment of FN 
are shown in Fig. 1. FN-C/H II or CS1 synthetic pcptide/OA 
conjugates (50 pg/ml) promoted the adhesion of virtually 
100%  of the  input ceils in a  90-min  cell adhesion assay, 
whereas lower coating concentrations (3-5 #g/ml) promoted 
melanoma cell adhesion at levels of '~50%  of input cells 
(data not shown). 
Since  peptide  FN-C/H  H  binds  3[H]heparin,  whereas 
CS1 does not (McCarthy et al., 1988b,  1990), we evaluated 
the ability of soluble heparin to inhibit mouse melanoma cell 
adhesion to the two synthetic peptides. Cell adhesion to sub- 
strata coated with  3  #g/ml  of FN-C/H II-OA was  signifi- 
candy inhibited in the presence of nanogram levels of soluble 
heparin, and inhibition was complete in the presence of 0.5 
#g/ml of soluble heparin (Fig. 2 a). By contrast, cell adhe- 
sion to CS1-OA was totally resistant to the effects of soluble 
heparin,  even  at concentrations  (5  pg/ml) of heparin that 
were 10-fold higher than those that maximally inhibited cell 
adhesion to FN-C/H II. 
To  further define the nature of the cell surface PG that 
might mediate mouse melanoma cell adhesion to FN-C/H II, 
we examined the ability of specific GAG-degrading enzymes 
to  interfere  with  mouse  melanoma cell adhesion.  Mouse 
melanoma  cells  were  pretreated  with  heparitinase,  then 
added to FN-C/H II-OA- and CS1-OA-coated substrata (Fig. 
2  b).  Heparitinase  digestion  resulted  in  a  concentration- 
dependent inhibition of adhesion to FN-C/H II-OA, and in- 
hibition was complete (90%) at 0.10  U  of enzyme.  Mouse 
melanoma cell adhesion  to the control synthetic peptide, 
CS1-OA, was unaffected by heparitinase digestion. By con- 
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Cell Adbt~ioa  r 
2039 
F/gum L ~tion  of  the 33-kD 
heparin binding fragment and 
synthetic peptides, FN-C/H II 
and CS1, within the intact FN 
molecule. The Illcs region is 
found only in the A isoforms 
of  human  plasma  FN.  The 
amino  and  carboxy  ends  of 
the 33-kD fragment are based 
on  previous  sequence  data 
(McCarthy et al., 1988b).  Se- 
lected biological domains, in- 
dicated by  roman numerals,  arc 
based on the nomenclature of 
Furcht  (1981).  I,  weak  heparin 
binding;  11,  collagen  binding; 
HI, free  sulfnydryl;  IV,  RGD- 
mediated  cell adhesion; V, 
carboxy-terminal  strong  hepa- 
fin  binding  and cell  adhesion; 
VI, free  sulfhydryl. Approxi- 
mate locations of tryptic (T) 
and cathepsin D (C) sites on intact FN are shown. The pepfide sequences (a), heparin binding properties (b), and cell adhesion properties 
(c) are summarized and based on McCarthy et al. (1988a,  1990) and Haugen et al. (1990). 
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trast, chondroitinase ABC pretreatment of  cells had no effect 
on cell adhesion to FN-C/H II-OA- or CS1-OA-coated sub- 
strata (Fig. 2 c). Cell viability, as determined by trypan blue 
dye exclusion, was >95 % following all enzyme treatments. 
These results suggest a primary involvement of cell surface 
HS, but not CS, in mediating the initial adhesion of mouse 
melanoma cells to peptide FN-C/H II. 
Isolation and Partial Characterization of Mouse 
Melanoma Cell Surface HSPG 
Mouse melanoma cell surface HSPG was purified from de- 
tergent  extracts  of  [35S]sulfate-labeled  mouse  melanoma 
cells grown in vitro by HPLC-DEAE chromatography.  35S- 
macromolecules eluted as three peaks from this column (Fig. 
3 a). The central peak, eluting at 0.32 M NaC1, was pooled 
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Figure  2.  Mouse melanoma cell adhesion to FN-C/H II (but not 
CS1) is HS-dependent. (.4) Mouse melanoma cells were added to 
96-well  plates  adsorbed  with 5  /zg/ml of FN-C/H II-OA (open 
squares) or CS1-OA  (solid squares) that had been  preincubated  with 
increasing concentrations of heparin. (B)  Mouse melanoma cells 
were pretreated  with increasing concentrations of heparitinase and 
then added to wells adsorbed with 5/zg/ml of FN-C/H II-OA (open 
squares) or CS1-OA (solid diamonds).  (C) Mouse melanoma cells 
were pretreated  with chondroitinase ABC at 0.1 U/ml then added 
to wells adsorbed with 5/~g/ml of FN-C/H II-OA (solid bars)  or 
CS1-OA (hatched bars). 
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Figure  3.  HPLC-DEAE purification of detergent-extracted  35S- 
protcoglycans  from mouse melanoma cells.  (,4)  35S-labeled ex- 
tracts were dialyzed into DEAE buffer (see Materials and Methods) 
and applied  to a HPLC-DEAE column and eluted  with a linear 
NaCI gradient. Fractions of 1 ml were monitored for radioactivity 
(open  squares)  and the salt  gradient monitored by conductivity 
measurements  (solid d/amonds). The bar indicates  the fractions 
that were pooled and rechromatographed  (B). 
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3  b).  Characterization of the 35S-GAGs in this peak indi- 
cated that it contained 99%  HS, as determined by nitrous 
acid sensitivity and resistance to chondroitinase ABC. The 
other two HPLC-DEAE peaks,  representing 35S-glycopro- 
teins  (0.21 M  NaC1) and  chondroitinase ABC-sensitive 
35S-CSPG (0.38 M NaCI), were not characterized further in 
these studies.  35S-HSPGs purified by HPLC-DEAE were 
subjected to chromatography on Sepharose CL-4B in 4 M 
guanidine and detergent. 35S-HSPG eluted as a single peak 
at K,v ,,00.45 (Fig. 4). 35S-HS, released from core proteins 
by alkaline borohydride, elated as a single peak from these 
columns at K,~ ,x,0.62. ~sS-HSPGs were also analyzed by 
Sepharose CL-6B chromatography using 0.5 M sodium ace- 
tate and 0.2% CHAPS as the buffer. The intact HSPG elated 
with a  K,v  ,v0.20  and  alkaline  borohydride released  HS 
elated with a K,v ,,00.40 (data not shown). 
35S-HSPGs purified by HPLC-DEAE and Sepharose CL- 
4B were iodinated to identify putative HSPG core proteins. 
nq-labeled samples were subjected to separation by SDS- 
PAGE and visualized by autoradiography (Fig. 5). Digestion 
of samples with heparitinase resulted in the appearance of a 
core protein with a Mr of 63 and a minor core protein with 
a M, of 32 (Fig. 5, lane 2). Under nonreducing conditions, 
the major core protein appeared slightly smaller (Mr 57), 
while  the  M,  of the  minor  species  remained  unchanged 
(Fig. 5, lane 4).  In subsequent HSPG preparations the Mr 
32 band was much reduced or absent. Undigested samples, 
or samples digested with chondroitinase ABC (Fig. 5, lanes 
I  and 3,  respectively), failed to  generate protein bands, 
confirming  the specificity  of  the heparitinase digestion. Sam- 
pies were also digested with both heparitinase and chon- 
droitinase ABC and yielded a single band at 63 kD, thus, 
suggesting that the sample did not contain a HS/CS hybrid 
proteoglycan (data not shown). While iodinated samples ap- 
peared to contain contaminating proteins due to the presence 
of minor bands in all lanes, their appearance was not the re- 
sult of enzymatic digestion with either chondroitinase ABC 
or heparitinase. 
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Figure 4. Analysis of HPLC-DEAE-purified 3SS-HSPG by Seph- 
arose CL-4B chromatography before (open squares) and after 
(solid diamonds) release of 3SS-HS by alkaline borohydride. Ra- 
dioactivity was monitored for each l-ml fraction. 
Figure 5. Identification of 63- 
kD core protein of  mouse mel- 
anoma  HSPG  by  autoradi- 
ography. '2~I-labeled HSPGs 
were digested and analyzed  by 
12.5% SDS-PAGE under re- 
ducing (R)  and nonreducing 
(NR) conditions. (Lane 1) Un- 
digested  HSPG; (lanes  2 and 4 ) 
heparitinase-digested HSPG; 
(lane 3) chondroitinase  ABC- 
digested HSPG. Relative mo- 
bilities  of  the molecular  weight 
standards  (xl03)  are  indi- 
cated at the right. 
Characterization of  Anti-mouse Melanoma 
HSPG Antibodies 
HSPG purified from mouse melanoma grown in vivo (see 
Materials and Methods) were injected into rabbits to gener- 
ate anti-HSPG antibodies. The anti-HSPG IgG was used to 
stain mouse melanoma cell cultures by indirect immunofluo- 
rescence. As shown in Fig. 6, the antisera stained the cell 
surface of melanoma cells in a punctate fashion (Fig. 6 a). 
Control  cultures  incubated  with  normal  rabbit  IgG  and 
rhodamine-conjugated goat anti-rabbit secondary antibody 
were negative (Fig. 6 b). 
The anti-HSPG IgG fraction was tested for its ability to 
react with HSPG or HSPG core proteins isolated from mouse 
melanoma cells grown in vivo or in vitro (Fig. 7). Western 
blots of intact HSPG, isolated from melanoma grown in vivo 
and electrophoresed in agarose-polyacrylamide gels, dem- 
onstrated that the anti-HSPG IgG reacted with a single, chon- 
droitinase-resistant, heparitinase-sensitive band (Fig. 7 a). 
The anti-HSPG IgG also reacted strongly with the 63-kD 
core protein produced by heparitinase digestion of HSPG 
that had been extracted and purified from mouse melanoma 
cells grown in vitro (Fig. 7 b), or in vivo (data not shown). 
This purified, adsorbed anti-HSPG IgG also cross-reacted 
with the smaller core protein species at Mr 32.  In control 
experiments, anti-HSPG IgG did not detect proteins from a 
mouse melanoma cell lysate (Fig. 7 b). K1735 mouse mela- 
noma cells also express a CD44-related cell surface CSPG 
with a core protein of I10 kD (Faassen et al.,  1992).  Anti- 
HSPG IgG failed to detect the ll0-kD CSPG core protein 
by Western blot (data not shown). 
Since mRNA for the large basement membrane HSPG 
core protein has previously been detected within these cells 
(Noonan et al.,  1988),  we also examined whether or not 
mouse melanoma HSPG core protein could be detected with 
a polyclonal antibody to the major EHS basement membrane 
HSPG, perlecan (HasseU et al.,  1980).  By immunoblot of 
heparitinase digests of mouse melanoma HSPG, we deter- 
mined that the 63- or 32-kD HSPG core proteins from mouse 
melanoma cells were not detected by anti-perlecan antibod- 
ies. In control experiments, anti-perlecan antibodies recog- 
nized a 400-kD HSPG core protein isolated from EHS tumor 
(data not shown). 
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ing of cultured mouse mela- 
noma  cells  with  anti-HSPG 
antibodies. Mouse melanoma 
cells grown in tissue culture 
were trypsin released and cul- 
tured on glass coverslips over- 
night. Coverslips  were  prepared 
for  indirect  immunofluores- 
cence (see Materials and Meth- 
ods) with anti-HSPG IgG (A) 
or  normal  rabbit  IgG  (B). 
Bar, '~20 t~m. 
Mouse Melanoma HSPG Is Anchored through PI 
Hydrophobic  chromatography  has  been  used  by  others 
(Yanagishita et al., 1987) to identify cell surface HSPGs that 
are  potentially  integral  components of the  plasma  mem- 
brane. One method of anchorage to the plasma membrane 
occurs through PI (Low and Sattiel,  1988) and can be re- 
moved by digestion with PI-PLC. To determine the hydro- 
phobic  properties  and  PI-PLC  sensitivity  of  detergent- 
extracted, HPLC-DEAE-purified 35S-HSPG, samples were 
pretreated  (or  not)  with  PI-PLC  and  applied  to  Octyl 
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Figure 7. Immunoreactivity of anti-HSPG IgG antibodies by West- 
ern blot. (A) HSPG purified from mouse melanoma grown in vivo 
was digested and analyzed by 0.6% agarose-l.8% polyacrylamide 
gel  electrophoresis  and  electroblotted.  (Lane  I)  Heparitinase- 
digested  HSPG;  0ane 2) chondroitinase  ABC--digested HSPG; 
(lane 3) undigested HSPG. The migration of rat chondmsareoma 
CSPG  (RCA) (M, 2.6  x  106) is  indicated.  (B) HSPG purified 
from mouse melanoma grown in vitro was digested and analyzed 
by  6-15 % SDS-PAGE  under reducing conditions and eleetroblotted. 
(Lane 1) Total cell extracts from mouse melanoma cells; (lane 2) 
heparitinase alone; (lane 3) heparitinase-digested HSPG; (lane 4) 
undigested HSPG. The membranes were probed with anti-HSPG 
IgG (1:50). Relative mobilities of the molecular weight standards 
(xl&) are indicated at the right. 
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Figure 8. Analysis of 35S-HSPG  by Octyl Sepharose CL-4B chro- 
matography before (A) and after (B) PI-PLC digestion. Fractions 
were monitored for radioactivity (open diamonds) and columns 
were eluted with a linear gradient of  column buffer containing Tri- 
ton X-100 (solid diamonds). 
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Intactt  0.2 
Immunoreactive 63-kD core proteinw  45 
* 3H dpmP~S dpm ratio. 
r Mouse melanoma cultures were metabolically labeled with 3H-ethanolamine 
and 3sS-sulfate and HSPG was purified from detergent extracts by HPLC- 
DEAE and dissociative CL-4B chromatography. An aliquot was analyzed for 
the presence of 3H and ~sS by liquid scintillation using a dual label program. 
w  Purified, dual labeled HSPG was heparitinasr digested and  analyzed by 
SDS-PAGE and Western blot. The immunoreaetive 63-kD band was excised 
and ~H and ~sS were determined by liquid scintillation. 
Sepharose columns (Fig. 8). Approximately 80 % of the un- 
treated  35S-HSPG bound  to  an  Octyl  Sepharose  column 
(Fig.  8  a).  The majority (70%)  of the bound 35S-HSPG 
eluted close to the critical micelle concentration of Triton 
X-100. In contrast, detergent-extracted HSPGs treated with 
PI-PLC did not bind to Octyl Sepharose and are seen in the 
A 
2~r 
unbound fractions (Fig. 8 b). In each case, the percent recov- 
ery of 35S-HSPG from the Octyl Sepharose columns was 
>99%.  Detergent-extracted,  HPLC-DEAE-purified  35S- 
HSPG digested with low levels of trypsin, or alkaline boro- 
hydride-released 3sS-HS, also  failed to bind this column 
(data not shown). These data demonstrate that detergent- 
extracted HSPG can bind to Oetyl Sepharose and that this 
binding is sensitive to the effects of PI-PLC, suggesting that 
the mouse melanoma HSPG core protein is anchored to the 
plasma membrane by PI. 
To provide additional evidence that the HSPG is linked to 
the cell surface via a PI-anchor, mouse melanoma cells were 
metabolically labeled with both 3H-e~anolamine and 3sS- 
sulfate. The cells were detergent extracted as previously de- 
scribed and the HSPG was purified over sequential HPLC- 
DEAE columns and dissociative Sepharose CL-4B columns. 
The resulting dual-labeled HSPG preparation was then quan- 
titated for relative amounts of both radioisotopes, yielding 
a 3H/35S ratio of 0,2 (Table I). This purified HSPG was then 
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Figure 9. 35S-HSPG and 3sS-HS bind to a FN-C/H II-OA affinity colunm. Detergent-extracted HPLC-DEAE-purified 3sS-HSPG was ap- 
plied to a FN-C/H II-OA (.4) or CS1-OA (B) affinity column in 50 mM Tris, pH 6.8, 50 told NaCl, 0.2% CHAPS and eluted with a NaCI 
gradient.  Alkaline borohydride-released 3sS-HS (C) or heparitinase-treated  ~Zq-HSPG (/9)  were applied to a  FN-C/H II-OA affinity 
column. Radioactivity was monitored for each 1-2-rnl fraction (open squares) and the salt gradient was determined by conductivity measure- 
ments (solid diamonds). 
The Journal of Cell Biology, Volume 117, 1992  1338 heparitinase digested,  subjected to  SDS-PAGE,  and elec- 
trophoreticaily transferred to nylon membranes.  The im- 
munoreactive 63-kD band was then identified by Western 
blot, and further analyzed by autoradiography. The results 
demonstrated that the immunoreactive 63-kD core protein 
from dual-labeled cultures could also be detected by autora- 
diography (not shown). The immunoreactive/radioactive  63- 
kD band was then excised from the nylon membrane, and 
determined to have a 3H/35S ratio of  45 (Table I), demonstrat- 
ing that the 63-kD heparitinase-digested core protein does 
label  with  3H-ethanolamine.  Collectively, these data pro- 
vide evidence that the 63-kD HSPG core protein of mouse 
melanoma cells is anchored to the plasma membrane via PI 
due to its sensitivity to PI-PLC digestion and due to the abil- 
ity of  the I-ISPG core protein to be metabolically labeled with 
3H-ethanolamine. 
HSPG Binds FN-C/H H  and Initiates Melanoma 
Cell Adhesion 
Virtually  100% of  the 35S-HSPG isolated from melanoma 
cells grown in vitro bound to FN-C/H II-OA affinity columns 
(Fig.  9  a),  under conditions for which no binding of 3sS- 
HSPGs  occurred  to  OA-OA  columns  (not  shown).  The 
bound  35S-HSPGs  could  be  eluted  from  FN-C/H  II-OA 
columns at 0.25 M NaC1 using a linear NaC1 salt gradient. 
The 35S-HSPGs  did not bind to CS1-OA  affinity columns 
(Fig. 9 b). To determine the relative importance of HS versus 
HSPG core protein in binding to peptide FN-C/H II, 35S- 
HS GAGs released by alkaline borohydride, or m25I-labeled 
HSPG core protein generated by heparitinase digestion of 
~25I-labeled HSPG, were applied to FN C/H-II-OA affinity 
columns. In the former case, 98 % of 35S-HS applied to the 
FN-C/H II-OA column bound to this column and was eluted 
at 0.25 M NaC1,  using a linear salt gradient (Fig. 9 c). The 
elution profile of 35S-HS was  thus  essentially identical to 
the  elution profile of the  intact 3sS-HSPGs.  By contrast, 
~25I-labeled HSPG core protein applied to the column did not 
bind and was collected in the unbound fractions (Fig. 9 d). 
Purified anti-HSPG IgG inhibited mouse melanoma cell 
adhesion to FN-C/H-II-coated substrata (Fig.  10 a).  This 
inhibition was concentration-dependent and 80 % inhibition 
was  observed in the  presence of 500 #g/ml  of total IgG 
purified from immune sera. In contrast, anti-HSPG had no 
effect on cell adhesion to CS1-OA (Fig.  10 a), and normal 
rabbit IgG had no effect on cell adhesion to either peptide, 
suggesting  the  inhibitory  effect of  anti-HSPG  IgG  was 
specific in nature. Anti-HSPG IgG Fab monomers inhibited 
mouse melanoma cell adhesion to FN-C/H II to approxi- 
mately the same level (80%) as anti-HSPG IgG (Fig.  10 b). 
Although  anti-HSPG  Fab  monomers  appear  to  be  more 
effective than intact immune IgG, the inhibition is identical 
if the concentrations of IgG and Fab monomers are com- 
pared on a molar basis.  Normal rabbit IgG Fab monomers 
had no effect on cell adhesion to FN-C/H II. Anti-HSPG Fab 
monomers had no effect on cell adhesion to CS1  (data not 
shown). 
Discussion 
The current studies demonstrate that cell surface HSPG of 
mouse  melanoma  cells  initiates  cellular  recognition and 
adhesion to a synthetic heparin-binding peptide FN-C/H II, 
Figure 10. Anti-HSPG inhibits 
mouse  melanoma cell adhe- 
sion to FN-C/H II. (.4) Mouse 
A  melanoma cells were pretreat- 
'~-----i=~~f_  ed for 15 min with increasing 
....  ~  concentrations  of anti-HSPG 
adsorbed  with  5  /zg/ml FN- 
*."  C/H II-OA (open squares)  or 
|  :  CS1-OA (solid squares).  Ad- 
o  .  ditionally, cells were pretreat- 
.....  ~  ~  ~  ed with normal rabbit IgG and  uglml 
added to wells adsorbed with 
FN-C/H II-OA (open circles). 
e  (B)  Mouse  melanoma  cells 
~L~  _  were p~e~med with anfi-HSPG  ,oo~ IgG  Fab  monomers  (solid 
~  '~  squares),  anti-HSPG  IgG 
,  .o  (open  squares),  or  normal 
rabbit  IgG  Fab  monomers 
(open  circles),  then added to 
o0  .......  wells  adsorbed with 5 /zg/ml 
.....  FN-C/H II-OA. 
derived from the 33-kD carboxy-terminal fragment of FN 
A-chains. Initial mouse melanoma cell adhesion to FN-C/H II 
is largely HS-dependent, since cell adhesion to this peptide 
is  sensitive  to  heparitinase  but  not  chondroitinase  ABC 
digestion. The mouse melanoma HHSPG  identified has prop- 
erties of an integral cell membrane molecule (Hook et al., 
1984; Yanagishita et al.,  1987) and is anchored through PI, 
since purified HSPG bound an Octyl Sepharose column, and 
upon digestion with PI-PLC, the HSPG binding was inhib- 
ited.  This was confirmed by the metabolic labeling of the 
HSPG core protein with 3H-ethanolamine, a method used 
to label the PI-anchor moiety (David et al.,  1990; Brunner 
et al., 1991). Furthermore, neutralizing anti-HSPG antibod- 
ies stain the surface of adherent melanoma cells in a punc- 
tate  fashion.  These results  strongly  support a  role for a 
PI-anchored HSPG in the initial recognition and adhesion 
of highly metastatic mouse melanoma cells to peptide FN- 
C/H II. 
Iodination of the I-ISPG followed by heparitinase digestion 
and  SDS-PAGE  analysis  demonstrated  that  the  isolated 
HSPG contains a major 63-kD core protein and a much less 
prevalent 32-kD peptide. Both core proteins were recognized 
by the polyclonal anti-HSPG antibody used in these studies. 
While it is possible that the two core proteins represent two 
distinct gene products, the appearance of the smaller band 
was  variable  from preparation to preparation,  suggesting 
that it may represent a proteolytic fragment of the larger 63- 
kD protein core. Comparison of the Sepharose CL-6B K,r 
for the intact HSPG or for alkaline borohydride released I-IS 
with  previously  established  standards  (Wasteson,  1971; 
Heingard and Hascall, 1974) indicates that the HSPG has an 
estimated molecular mass of 150-175 kD with HS chains of 
20-25 kD. Considering the estimated size of the HS core 
protein, we would predict that the melanoma HSPG iden- 
tiffed in these studies has two to four HS/core protein, which 
is similar to what has been observed for other previously de- 
scribed cell surface HSPGs (Gallagher,  1989). 
While the exact identity of the core protein(s) identified in 
the current study has not yet been established, there are bio- 
chemical and immunological data  that may be helpful to 
Drake et al. Heparan Sulfate Proteoglycan Adhesion to Fibronectin  1339 determine  the  potential  relationship  to  other  previously 
identified core proteins. Analysis of the major melanoma 
HSPG core protein by reducing and nonreducing SDS-PAGE 
indicates that it contains several intrachain disulfide bonds 
and is PI-PLC sensitive, thereby differentiating it from syn- 
decan, which contains only a  single cysteine residue and 
contains a transmembrane domain (Saunders et al.,  1989). 
Additionally, because these cells express mRNA for the large 
basement membrane HSPG core protein, we examined the 
immunological cross-reactivity of mouse melanoma HSPG 
core protein(s) with a polyclonal antibody to the major EHS 
basement membrane HSPG, perlecan (Hassell et al., 1980). 
Mouse melanoma 63- and 32-kD HSPG core proteins did 
not react with anti-perlecan antibodies, although we can not 
rule out the possibility that the mouse melanoma HSPG may 
represent a processed form of the large basement membrane 
HSPG.  The 63-kD  mouse melanoma cell surface HSPG 
does, however, share a number of properties with glypican, 
a cell surface HSPG described in human lung fibroblasts. 
Glypican has an estimated core protein molecular mass of 
64 kD after heparitinase digestion which is similar to the es- 
timated size of the melanoma HSPG, and upon reduction it 
exhibits a similar shift in apparent molecular mass. Glypican 
has also been shown to be linked via phosphatidylinositol 
(David et al., 1990), as has another HSPG of Schwann calls 
(Carey and Stahl,  1990).  Whether or not these PGs are 
structurally related to the melanoma cell surface HSPG will 
be determined in future studies. 
Our data support a model in which cell surface HS initi- 
ates mouse melanoma cell adhesion to FN-C/H II. This is 
consistent with previous studies which identify the glycos- 
aminoglycan portion of several proteoglycans as important 
binding sites for ECM-related and other ligands (Hook et 
al., 1984; Ruoslahti, 1988; GaUagher, 1989). UsingFN-C/H 
II-OA affinity  column chromatography we demonstrated that 
mouse melanoma HSPG and alkaline borohydride-released 
HS bind FN-C/H II with the same relative affinity, while the 
core protein does not bind to FN-C/H-II under the same con- 
ditions. Moreover, pretreatment of mouse melanoma cells 
with heparitinase completely inhibited cell adhesion to FN- 
C/H II-OA-coated substrata. The specificity of the action of 
heparitinase  on  FN-C/H-II-mediated  cell  adhesion  was 
demonstrated by the failure of the enzyme to inhibit cell ad- 
hesion to the control peptide CS1, as well as by the failure 
of chondroitinase ABC to inhibit melanoma cell adhesion to 
FN-C/H II. Importantly, these data distinguish these cells 
from A375 SM human melanoma cells, which express little, 
if any, cell surface HSPGs (Iida et al., 1992).  As might be 
expected, human melanoma cell adhesion to FN-C/H-II is 
completely heparitinase-resistant, but is partially sensitive 
to the effect of chondroitinase ABC (Iida et al., 1992).  Col- 
lectively, the results from both studies suggest that FN-C/H- 
II may mediate the adhesion of different cell types in a cell 
type-specific fashion. 
We have shown that mouse melanoma cell adhesion to FN- 
C/H II is initiated via a HS-dependent mechanism. However, 
anti-HSPG core protein antibodies, which we have deter- 
mined to lack HS reactivity (data not shown), can also in- 
hibit ceil adhesion to substrata coated with this synthetic 
peptide. Because anti-HSPG IgG Fab monomers inhibit cell 
adhesion to FN-C/H II to the same degree, inhibition of cell 
adhesion to FN-C/H II is not likely to be a result of cell sur- 
face HSPG redistribution or endocytosis induced by the anti- 
HSPG antibodies. Moreover, we have not been able to dis- 
rupt binding of  purified HSPG to FN-C/H II affinity  columns 
using the anti-HSPG antibodies, suggesting that the inhibi- 
tory effects of anti-HSPG on cell adhesion are most likely 
not due to the ability of the anti-HSPG to disrupt HSPG/ 
FN-C/H H interactions. 
While the mechanism(s) of inhibition of the anti-HSPG 
IgG on  melanoma cell  adhesion  to  FN-C/H  1I  remains 
undefined, it would seem that the core protein plays an im- 
portant role in mediating cell adhesion that is independent 
of  direct HSPG binding to FN-C/H 1I. One possibility is that 
the PI-anchored HSPG core protein could laterally associate 
with other cell surface adhesion molecules following initial 
binding to FN-C/H II, and possibly stabilize cell adhesion 
to FN-C/H II. In support of  this hypothesis are studies which 
demonstrate that PI-anchored proteins have a tenfold greater 
lateral mobility in the plasma membrane than other integral 
membrane proteins  (reviewed in  Cross,  1990).  Alterna- 
tively, it is possible that FN-C/H-II-mediated ligation of the 
HSPG can somehow activate specific signal transduction 
pathways associated with PI turnover. Although it has been 
suggested that PI-anchored proteins such as Thy-1 (a PI- 
anchored glycoprotein on neurons and thymocytes) can play 
a  role in signal transduction (Kroczek et al.,  1986),  the 
mechanism by which sueh proteins can transmit signals is 
not yet clear.  Further characterization of this melanoma- 
associated HSPG (designated as MPIHP-63 for melanoma- 
associated phosphatidylinositol-anchored HSPG) will yield 
new  insights  into  the  molecular  basis  for  proteoglycan- 
mediated melanoma cell recognition of the ECM, and could 
contribute important new concepts  for understanding the 
biology of tumor cell adhesion, invasion, and metastasis. 
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